← Eichor
Study identifier: NCT04265040 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

Condition: Non-ischemic Cardiomyopathy · DCM - Dilated Cardiomyopathy · HCM - Hypertrophic Cardiomyopathy  ·  Sponsor: University Hospital Heidelberg

PhaseN/A
Planned participants2040
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity. This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. "Clinical phenotyping, follow-up \& biosampling" 2. "Genomics", 3. "Inflammation" and 4. "Biomarker". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for o…

This description comes directly from the study's public registry record.

Talk to the study team

Farbod Sedaghat-Hamendani, Dr.  ·  +496221/56-8676  ·  Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de

Johannes Trebing, Dr.  ·  Johannes.Trebing@med.uni-heidelberg.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital Heidelberg - Clinic of Cardiology, Angiology and PneumologyHeidelberg, Baden-Wurttemberg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04265040